Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Fox

Showing results (111-120 of 120) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 120 results.
Journal of Medicinal Chemistry|April 24, 2019
Design and Synthesis of Selective Phosphodiesterase 4D (PDE4D) Allosteric Inhibitors for the Treatment of Fragile X Syndrome and Other Brain DisordersMark E Gurney, Richard A Nugent, Xuesheng Mo, et al.
Nature Neuroscience|August 6, 2013
Top3β is an RNA topoisomerase that works with fragile X syndrome protein to promote synapse formationDongyi Xu, Weiping Shen, Rong Guo, et al.
Antimicrobial Agents and Chemotherapy|December 25, 2013
A structural biology approach enables the development of antimicrobials targeting bacterial immunophilinsDarren W Begley, David Fox, Dominic Jenner, et al.
Plos Biology|May 22, 2018
Insight into small molecule binding to the neonatal Fc receptor by X-ray crystallography and 100 kHz magic-angle-spinning NMRDaniel Stöppler, Alex Macpherson, Susanne Smith-Penzel, et al.
Nature Communications|September 21, 2019
Harnessing calcineurin-FK506-FKBP12 crystal structures from invasive fungal pathogens to develop antifungal agentsPraveen R Juvvadi, David Fox, Benjamin G Bobay, et al.
Nature Communications|July 3, 2025
Author Correction: Harnessing calcineurin-FK506-FKBP12 crystal structures from invasive fungal pathogens to develop antifungal agentsPraveen R Juvvadi, David Fox, Benjamin G Bobay, et al.
The Journal of Antimicrobial Chemotherapy|March 4, 2022
Broad-spectrum in vitro activity of macrophage infectivity potentiator inhibitors against Gram-negative bacteria and Leishmania majorJua Iwasaki, Donald D Lorimer, Mirella Vivoli-Vega, et al.
Plos One|February 6, 2013
Combining functional and structural genomics to sample the essential Burkholderia structomeLoren Baugh, Larry A Gallagher, Rapatbhorn Patrapuvich, et al.
American Journal of Hematology|February 7, 2025
Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated With R-GemOx: A Multicenter Cohort StudySamuel Yamshon, Jean L Koff, Melissa C Larson, et al.
Tuberculosis (Edinburgh, Scotland)|January 24, 2015
Increasing the structural coverage of tuberculosis drug targetsLoren Baugh, Isabelle Phan, Darren W Begley, et al.
Pageof 12

Showing results (111-120 of 120) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 120 results.
Journal of Medicinal Chemistry|April 24, 2019
Design and Synthesis of Selective Phosphodiesterase 4D (PDE4D) Allosteric Inhibitors for the Treatment of Fragile X Syndrome and Other Brain DisordersMark E Gurney, Richard A Nugent, Xuesheng Mo, et al.
Nature Neuroscience|August 6, 2013
Top3β is an RNA topoisomerase that works with fragile X syndrome protein to promote synapse formationDongyi Xu, Weiping Shen, Rong Guo, et al.
Antimicrobial Agents and Chemotherapy|December 25, 2013
A structural biology approach enables the development of antimicrobials targeting bacterial immunophilinsDarren W Begley, David Fox, Dominic Jenner, et al.
Plos Biology|May 22, 2018
Insight into small molecule binding to the neonatal Fc receptor by X-ray crystallography and 100 kHz magic-angle-spinning NMRDaniel Stöppler, Alex Macpherson, Susanne Smith-Penzel, et al.
Nature Communications|September 21, 2019
Harnessing calcineurin-FK506-FKBP12 crystal structures from invasive fungal pathogens to develop antifungal agentsPraveen R Juvvadi, David Fox, Benjamin G Bobay, et al.
Nature Communications|July 3, 2025
Author Correction: Harnessing calcineurin-FK506-FKBP12 crystal structures from invasive fungal pathogens to develop antifungal agentsPraveen R Juvvadi, David Fox, Benjamin G Bobay, et al.
The Journal of Antimicrobial Chemotherapy|March 4, 2022
Broad-spectrum in vitro activity of macrophage infectivity potentiator inhibitors against Gram-negative bacteria and Leishmania majorJua Iwasaki, Donald D Lorimer, Mirella Vivoli-Vega, et al.
Plos One|February 6, 2013
Combining functional and structural genomics to sample the essential Burkholderia structomeLoren Baugh, Larry A Gallagher, Rapatbhorn Patrapuvich, et al.
American Journal of Hematology|February 7, 2025
Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated With R-GemOx: A Multicenter Cohort StudySamuel Yamshon, Jean L Koff, Melissa C Larson, et al.
Tuberculosis (Edinburgh, Scotland)|January 24, 2015
Increasing the structural coverage of tuberculosis drug targetsLoren Baugh, Isabelle Phan, Darren W Begley, et al.
Pageof 12